Regulatory status: The FDA determined in 2022 that BPC-157 raises concerns that preclude its use in compounded preparations, placing it on the list of substances that may not be compounded under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
Both stimulate fibroblast proliferation and extracellular matrix production
Standard handling precautions for small-molecule research compounds apply
Laboratories using the compound in time-course or dose-response work should prepare fresh aliquots where possible, recording reconstitution date and storage temperature alongside each experimental block
Perhaps, even more troubling: chronic inflammation has been linked to dementia, schizophrenia, bipolar disorder, autism spectrum disorder, PTSD, and OCD, says Jandes
10.1080/03602530600952172 16 SharmaR.McDonaldT